A phase-II Trial of Corynebacterium Parvum as Adjuvant to Surgery in the Treatment of Operable Lung Cancer

Cancer Immunol Immunother. 1983;16(2):114-6. doi: 10.1007/BF00199242.

Abstract

A phase-II randomized trial has been undertaken in 49 patients with operable lung cancer, to determine the effect of a single IV infusion of killed C. parvum vaccine as an adjuvant to surgery. The number of patients was insufficient to provide a decisive result, but analysis 6 years after the last patient was admitted shows that the adjuvant therapy certainly did not shorten, and may well have prolonged, survival. Of the patients with squamous cell carcinoma who were alive 1 year after operation all except one in the C. parvum-treated group were alive 4 years later, whereas five in the control group died during this interval. Judgement concerning the value of IV administration of CP as adjuvant therapy in patients with operable lung cancer should be deferred until further evidence is available.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use*
  • Bacterial Vaccines / administration & dosage
  • Bacterial Vaccines / therapeutic use*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / surgery
  • Carcinoma, Squamous Cell / therapy
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Humans
  • Immunotherapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery
  • Lung Neoplasms / therapy*
  • Propionibacterium acnes / immunology*
  • Scotland

Substances

  • Adjuvants, Immunologic
  • Bacterial Vaccines